PSA values identify candidates for long-term ADT 2 Dec 2011 0 comments Prostate-specific antigen values can act as an early surrogate for prostate cancer-specific mortality, identifying patients most likely to benefit from long-term androgen suppression therapy,…
Check bone density before prostate cancer therapy 25 Mar 2011 0 comments Men with prostate cancer should have their bone mineral density measured before starting androgen deprivation therapy, according to new guidelines.
Annual PSA tests can be ruled out by initial result 18 Feb 2011 0 comments An initial PSA level of 3.0 ng/mL appears to be an appropriate threshold for biopsy of men to investigate for prostate cancer, a major new study suggests.
Brachytherapy better for QOL in prostate cancer 16 Dec 2010 0 comments Brachytherapy has less of a negative impact on patients with prostate cancer than radical prostatectomy, a Canadian study has shown.
Active surveillance a 'reasonable choice' in low-risk prostate cancer 3 Dec 2010 0 comments Active surveillance is a reasonable alternative to definitive treatment for a 65 year old man with low-risk prostate cancer, according to a detailed decision analysis model reported in JAMA.
Free PDF of Chapman's new prostate cancer book 19 Nov 2010 0 comments Men need to weigh up the significant risks as well as the benefits associated with being tested for prostate cancer, according to a new book from the University of Sydney.
No cognitive decline with ADT 5 Nov 2010 0 comments There is no evidence to suggest that androgen deprivation therapy has an impact on cognitive function in men with prostate cancer, a JCO paper concludes.
Hypofractionated radiotherapy beneficial in early prostate cancer 15 Oct 2010 0 comments Australian research has, for the first time, demonstrated the therapeutic advantages of hypofractionated radiotherapy in early-stage prostate cancer.
Gene test identifies indolent prostate cancers 23 Sep 2010 0 comments Australian urologists have helped develop a simple gene test that could change the management of early prostate cancers by discriminating between indolent and more aggressive cancers.
One-off PSA test at 60 tells all 16 Sep 2010 0 comments Screening for prostate cancer with PSA tests is not justified but a single PSA test at the age of 60 could be used to predict a man's lifetime risk of prostate cancer, two new studies suggest.
